What is BioCryst Pharmaceuticals's restricted cash?

BioCryst Pharmaceuticals (BCRX) reported restricted cash of $854K in Q1 2026.

How has BioCryst Pharmaceuticals's restricted cash changed year-over-year?

BioCryst Pharmaceuticals's restricted cash increased by 193.5% year-over-year, from $291K to $854K.

What is the long-term trend for BioCryst Pharmaceuticals's restricted cash?

Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's restricted cash has grown at a -38.2% compound annual growth rate (CAGR), from $2.22M to $201K.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

BioCryst Pharmaceuticals BCRX Restricted Cash

Restricted Cash at other companies

ALN

Alnylam PharmaceuticalsALNY

$1.64M-36.8%

Acadia PharmaceuticalsACAD

$7.85M-10.5%

Amneal Pharmaceuticals, Inc.AMRX

$4.17M-36.6%

CRISPR TherapeuticsCRSP

$7.63M-4.7%

BridgeBio PharmaBBIO

——

Regeneron PharmaceuticalsREGN

——

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's restricted cash?: BioCryst Pharmaceuticals (BCRX) reported restricted cash of $854K in Q1 2026.
How has BioCryst Pharmaceuticals's restricted cash changed year-over-year?: BioCryst Pharmaceuticals's restricted cash increased by 193.5% year-over-year, from $291K to $854K.
What is the long-term trend for BioCryst Pharmaceuticals's restricted cash?: Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's restricted cash has grown at a -38.2% compound annual growth rate (CAGR), from $2.22M to $201K.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.